Happy Poster
Type:
Happy Poster
Category:
Happy Poster
Place:
Arena Científica
Date and time:
21:20 to 22:20 on 06/07/2024
Share your questions or ideas about this activity!
Papers
PANEL 1
The importance and challenges of optic neuropathies late diagnosis.
PANEL 2
Longitudinally extensive myelitis as a first presentation of neurosarcoidosis
PANEL 3
Patient-reported outcomes (SymptoMScreen) in a Brazilian scenario: most affected symptoms and their correlations with conventional scales
PANEL 4
Silent bilateral optic papillitis after COVID-19: a case report.
PANEL 5
Impact of Comorbidities on Cognition in Multiple Sclerosis Patients: A Multivariable Analysis
PANEL 6
The Lyme disease as a differential diagnosis for Multiple Sclerosis
PANEL 7
Early High-efficacy Disease-modifying Therapy in Multiple Sclerosis: A 4-Year Real World Study
PANEL 8
IgG index versus oligoclonal bands in a Brazilian multiple sclerosis center
PANEL 9
DISABILITY FUNCTIONAL PROFILE OF PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS AND ITS ASSOCIATION WITH DISEASE MODIFYING THERAPY IN A HOSPITAL AT NORTHEAST OF BRAZIL
PANEL 10
Lower prevalence of cognitive impairment in a specific MS population: associated factors and probable reasons
PANEL 11
Longitudinally Extensive Transverse Myelitis: Impact on Functional Prognosis and Mortality in a 10-Year Follow-Up Cohort
PANEL 12
Fatigue and sleep disturbances predict depressive symptoms in people with Multiple Sclerosis
PANEL 13
COVID-19 AND VACCINATION IN CHILDREN AND ADOLESCENTS WITH NEUROIMMUNOLOGICAL DISORDERS
PANEL 14
Kappa index in the diagnosis of Multiple sclerosis
PANEL 15
Development of a clinical score to estimate the probability of neuromyelitis optica in patients presenting with optic neuritis
PANEL 16
Description of Suspected Autoimmune Encephalitis Cases in Two Neurological Reference Hospitals in Curitiba, Brazil
PANEL 17
Delayed diagnosis in multiple sclerosis: Unraveling risk factors in a Brazilian setting
PANEL 18
Family history of Multiple Sclerosis and other autoimmune diseases in Multiple Sclerosis
PANEL 19
Evolution of EDSS in patients with progressive multiple sclerosis.
PANEL 20
Impacts of environmental tobacco smoke on the onset and progression of multiple sclerosis: a systematic review
PANEL 21
Exploring Very Late-Onset NMOSD: Frequency and Clinical Features in Latin America
PANEL 22
Lost Time, Lost Function? Unraveling the Impact of Diagnosis Delay on Disability Progression in Multiple Sclerosis
PANEL 23
MIGRAINE IN MULTIPLE SCLEROSIS PATIENTS
PANEL 24
Epidemiological Study on Multiple Sclerosis in Brazil: Demographic and Clinical Characteristics According to Geographic Distribution – a BRANDO study
PANEL 25
Unveiling the Silent Threat: Exploring Latent Tuberculosis in Multiple Sclerosis Patients Undergoing Novel Therapies
PANEL 26
Do demographic and clinical outcomes differ between antidepressant users and non-users in MS?
PANEL 27
Antibody Awareness and Diagnosis Recognition in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: A Cross-Sectional Study
PANEL 28
Rituximab as a treatment of multiple sclerosis: a literature review.
PANEL 29
14 years of Natalizumab infusion experience in a Neuroimmunology service in Pernambuco
PANEL 30
Treatment for Multiple Sclerosis and Reactivation of Latent Tuberculosis, is there a relationship?
PANEL 31
Combination of Secukinumab and Natalizumab in the Treatment of a Patient with Psoriatic Arthritis and Multiple Sclerosis
PANEL 32
Real-world study of oral cladribine for Brazilian patients with multiple sclerosis: results from the BRANDO Registry
PANEL 33
Title: Early Relapse after Alemtuzumab treatment: A Case Report of Highly Active Multiple Sclerosis
PANEL 34
Understanding Hodgkin Lymphoma Occurrence After Fingolimod Withdrawal
PANEL 35
The long Journey to achieve high efficacy therapy – Alemtuzumab in Brazilian public scenario
PANEL 36
Cytokine Storms during Alemtuzumab Infusion: A case series
PANEL 37
Acute non-autoimmune hepatitis induced by Alemtuzumab: a case report
PANEL 38
Seronegative de novo Myasthenia Gravis induced by Alemtuzumab: a case report
PANEL 39
Impact of multiple sclerosis treatments on the rate of cerebral remyelination assessed by advanced neuroimaging
PANEL 40
Correlations between Multiple Sclerosis, Cognition, Human Development Index, and Social Vulnerability.
PANEL 41
The effect of total dietary antioxidant capacity (TDAC) in clinical and nutritional status in people with neuromyelitis optica spectrum disorder
PANEL 42
No correlation found between total dietary antioxidant capacity and multiple sclerosis phenotypes or EDSS
PANEL 43
REHABILITATION ACCESS PROFILE OF PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS IN REFERENCE CENTER AT NORTHEAST BRAZIL
PANEL 44
MS UNIT - FROM CONCEPT TO PRACTICE: ANALYSIS OF DEPRESSION, ANXIETY, FATIGUE, QUALITY OF LIFE AND PERCEPTION OF DISEASE OF PATIENTS WITH MULTIPLE SCLEROSIS FROM A PRIVATE MS UNIT IN RIO DE JANEIRO – A NURSE’S PERSPECTIVE
PANEL 45
The importance of a psycho-emotional support group for the quality of life of people with NMO
PANEL 46
Socio-emotional support for men with NMO
PANEL 47
Overlapping NMOSD-AQP4 and Bickerstaff Encephalitis: an intriguing case report
PANEL 48
Unveiling Inflamatory Optic Neuropathy with Silicone Oil Endotamponade: A Clinical Case
PANEL 49
Impact of motor and visual sequelae on the perception of functional performance in people with Neuromyelitis Optica
PANEL 50
Analyzing the Association Between Cancer and Neuromyelitis Optica: A Case Series
PANEL 51
Delay in Treatment Initiation for NMOSD: A Study of Timeframes in a Brazilian Cohort
PANEL 52
Confusion in Diagnosis: NMOSD Patients Mistakenly Treated for Multiple Sclerosis
PANEL 53
The Peculiar Implications of Immune-mediated Optic Neuritis at Disease Presentation in Brazil. Study of 271 Patients.
PANEL 54
Multiple sclerosis-related optic neuritis is an outlier in the autoimmune optic neuritis group. The 2022 International Panel Classification needs a prompt revision.
PANEL 55
Broadening NMOSD Etiology: Neurosyphilis as a Mimicry Factor
PANEL 56
Schistosomiasis mansoni-Associated Neuromyelitis Optica: An Unprecedent Case Report
PANEL 57
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) treated with IL-6 inhibitor (Tocilizumab) - experience from a Neuroimmunology reference center in a hospital in São Paulo.
PANEL 58
Results of social media and in-person NMOSD awareness campaigns: how can we measure their impact?
PANEL 59
Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil
PANEL 60
Mast cells: A key component in the pathogenesis of Neuromyelitis Optica Spectrum Disorder?
PANEL 61
![[object Object]](https://static.galoa.com.br/file/Eventmanager-Private/styles/attendee_dashboard_logo/s3/eventmanager_event/logo/Logo_31.png?VersionId=4_z9e083e414507696175f50716_f1111809d7fab9f12_d20240213_m140544_c003_v0312024_t0055_u01707833144955&itok=6Ntafve0 "[object Object]"){kind=logo}
